Integrated Financial Results for the Quarter and Financial Year ended March 31, 2026.
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.3 pts more than Nifty Microcap 250 and 11.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Novartis India reported FY2026 revenue from operations of ₹3,543.3 million, marginally lower than FY2025's ₹3,562.7 million. PAT declined to ₹931.8 million from ₹1,009.0 million the prior year, representing a 7.7% drop. The company proposed zero dividend for FY26 compared to ₹25 per share paid in FY25. A major ownership change is underway as Novartis AG has agreed to sell its 70.68% stake to WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners, triggering an open offer. The statutory auditor issued an unmodified opinion with no qualifications. Related party transactions include royalty payments to Novartis AG (holding company) and various service transactions with fellow subsidiaries.
The PAT decline of 7.7% and elimination of dividend are negative signals for income-seeking investors. However, the company remains debt-free with strong cash reserves of ₹6,677 million. The impending change in promoter from Novartis AG to new acquirers adds uncertainty about future strategic direction.